Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.44 |
| ▸ | OGA | O60502 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724423 | 0.93 | HRH3 (0.48) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL5723684 | 0.93 | HRH3 (0.48) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL5724059 | 0.87 | HRH3 (0.44) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL5723961 | 0.85 | OGA (0.45) | HRH3SMN1; SMN2OGARAB9ANPC1 | |
| SCHEMBL5723756 | 0.85 | OGA (0.45) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL5724336 | 0.82 | OGA (0.48) | HRH3SMN1; SMN2OGARAB9ANPC1 | |
| SCHEMBL5724211 | 0.81 | HRH3 (0.56) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL22048957 | 0.76 | OGA (0.52) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL28141436 | 0.76 | HRH3 (0.50) | HRH3SCDSMN1; SMN2OGARAB9A | |
| SCHEMBL5724256 | 0.76 | HRH3 (0.51) | HRH3SCDSMN1; SMN2OGARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | HRH3 3678/4885SCD 54/4885SMN1; SMN2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.